Clareo Health | A Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Failed First-Line Dacabazine or Temozolomide Contained Therapy
A Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Failed First-Line Dacabazine or Temozolomide Contained Therapy
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Yonsei University
Age
20–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with histologically proven malignant melanoma (recurred or metastatic) that had progressed during or after receiving at least one cycle of a regimen containing dacarbazine or temozolomide in the advanced setting
Measurable disease (RECIST)
ECOG performance 0-2
Adequate organ function
Total bilirubin \<1.5N ; ASAT and ALAT \<2.5N
Serum Creatinin \< 1.5N
ANC ≥ 1,500/mm³ (G-CSF allowed)
Platelets ≥ 100,000/mm³
Hb ≥ 9.0 g/dL
Life expectancy of at least 12 weeks
Signed Written Informed Consent
You may not be if
Symptomatic brain metastasis
Previous history of treatment with taxane or platinum agent containing chemotherapy
Previous major surgery within 2 weeks before the start of the trial, or a failure to recover from the surgery
Previous history of other malignancies within 5 years except for cured skin basal cell carcinoma or cured in-situ cervix cancer
Other severe medical conditions (infection, uncontrolled hypertension, heart failure, MI history within 6 months)
